154 related articles for article (PubMed ID: 23419529)
1. [Importance of the 11β-hydroxysteroid dehydrogenase enzyme in clinical disorders].
Feldman K; Likó I; Nagy Z; Szappanos A; Grolmusz VK; Tóth M; Rácz K; Patócs A
Orv Hetil; 2013 Feb; 154(8):283-93. PubMed ID: 23419529
[TBL] [Abstract][Full Text] [Related]
2. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
Draper N; Stewart PM
J Endocrinol; 2005 Aug; 186(2):251-71. PubMed ID: 16079253
[TBL] [Abstract][Full Text] [Related]
3. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
Tomlinson JW; Walker EA; Bujalska IJ; Draper N; Lavery GG; Cooper MS; Hewison M; Stewart PM
Endocr Rev; 2004 Oct; 25(5):831-66. PubMed ID: 15466942
[TBL] [Abstract][Full Text] [Related]
4. 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action.
Seckl JR
Curr Opin Pharmacol; 2004 Dec; 4(6):597-602. PubMed ID: 15525550
[TBL] [Abstract][Full Text] [Related]
5. Expression of 11β-hydroxysteroid dehydrogenase 1 and 2 in patients with chronic rhinosinusitis and their possible contribution to local glucocorticoid activation in sinus mucosa.
Jun YJ; Park SJ; Kim TH; Lee SH; Lee KJ; Hwang SM; Lee SH
J Allergy Clin Immunol; 2014 Oct; 134(4):926-934.e6. PubMed ID: 24810847
[TBL] [Abstract][Full Text] [Related]
6. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
7. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
8. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
9. 11beta-Hydroxysteroid dehydrogenase type 1-driven cortisone reactivation regulates plasminogen activator inhibitor type 1 in adipose tissue of obese women.
Ayachi SE; Paulmyer-Lacroix O; Verdier M; Alessi MC; Dutour A; Grino M
J Thromb Haemost; 2006 Mar; 4(3):621-7. PubMed ID: 16460444
[TBL] [Abstract][Full Text] [Related]
10. Application of ELISA Technique and Human Microsomes in the Search for 11
Kupczyk D; Studzińska R; Bilski R; Woźniak A
Biomed Res Int; 2019; 2019():5747436. PubMed ID: 31214617
[TBL] [Abstract][Full Text] [Related]
11. 11β-hydroxysteroid dehydrogenase types 1 and 2 activity in subcutaneous adipose tissue in humans: implications in obesity and diabetes.
Dube S; Norby BJ; Pattan V; Carter RE; Basu A; Basu R
J Clin Endocrinol Metab; 2015 Jan; 100(1):E70-6. PubMed ID: 25303491
[TBL] [Abstract][Full Text] [Related]
12. The rise in expression and activity of 11β-HSD1 in human mesenchymal progenitor cells induces adipogenesis through increased local cortisol synthesis.
Blaschke M; Koepp R; Streit F; Beismann J; Manthey G; Seitz MT; Kragl A; Siggelkow H
J Steroid Biochem Mol Biol; 2021 Jun; 210():105850. PubMed ID: 33639236
[TBL] [Abstract][Full Text] [Related]
13. Expression profiles of cortisol-inactivating enzyme, 11β-hydroxysteroid dehydrogenase-2, in human epidermal tumors and its role in keratinocyte proliferation.
Terao M; Itoi S; Murota H; Katayama I
Exp Dermatol; 2013 Feb; 22(2):98-101. PubMed ID: 23362866
[TBL] [Abstract][Full Text] [Related]
14. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.
Hughes KA; Webster SP; Walker BR
Expert Opin Investig Drugs; 2008 Apr; 17(4):481-96. PubMed ID: 18363514
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases.
Stegk JP; Ebert B; Martin HJ; Maser E
Mol Cell Endocrinol; 2009 Mar; 301(1-2):104-8. PubMed ID: 19022342
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.
Hamilton BS; Himmelsbach F; Nar H; Schuler-Metz A; Krosky P; Guo J; Guo R; Meng S; Zhao Y; Lala DS; Zhuang L; Claremon DA; McGeehan GM
Eur J Pharmacol; 2015 Jan; 746():50-5. PubMed ID: 25445047
[TBL] [Abstract][Full Text] [Related]
17. Endocrine disruptors and other inhibitors of 11β-hydroxysteroid dehydrogenase 1 and 2: Tissue-specific consequences of enzyme inhibition.
Vitku J; Starka L; Bicikova M; Hill M; Heracek J; Sosvorova L; Hampl R
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt B):207-16. PubMed ID: 25066675
[TBL] [Abstract][Full Text] [Related]
18. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol.
Morris DJ; Latif SA; Hardy MP; Brem AS
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):161-8. PubMed ID: 17459698
[TBL] [Abstract][Full Text] [Related]
19. Alteration of the cortisol-cortisone shuttle in leprosy type 1 reactions in leprosy patients in Hyderabad, India.
Andersson AK; Atkinson SE; Khanolkar-Young S; Chaduvula M; Jain S; Suneetha L; Suneetha S; Lockwood DN
Immunol Lett; 2007 Mar; 109(1):72-5. PubMed ID: 17320974
[TBL] [Abstract][Full Text] [Related]
20. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
Gathercole LL; Stewart PM
J Steroid Biochem Mol Biol; 2010 Oct; 122(1-3):21-7. PubMed ID: 20347978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
